Celltrion


Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Jung Jin Seo, is the second-richest person in South Korea.

History

In 1999, Nexol, Inc. was founded as a global business management consulting firm. In 2002, Celltrion, Inc. was founded as a biopharmaceutical company.
In 2008, Nexol and Celltrion established a global distribution agreement.
In 2009, distribution channels were established in America, Oceania, Europe and Nexol, Inc. renamed as Celltrion Healthcare Co., Ltd.
In 2010, distribution channels were established in Japan, Commonwealth of Independent States, Eastern Europe, and the Middle East.
In 2013, distribution channels were added in Europe.

Products

The company's products are manufactured at mammalian cell culture facilities designed and built to comply with the United States FDA’s cGMP, and the European Medicines Agency’s GMP standards.

Inline product

is a biosimilar monoclonal antibody against tumor necrosis factor alpha, approved by the European Medicines Agency for treatment of:
  1. rheumatoid arthritis,
  2. adult Crohn's disease,
  3. pediatric Crohn's disease,
  4. ulcerative colitis,
  5. pediatric ulcerative colitis,
  6. ankylosing spondylitis,
  7. psoriatic arthritis, and
  8. psoriasis.
In 2012 Remsima was approved by the Republic of Korea's Ministry of Food and Drug Safety, previously known as Korea Food and Drug Administration and in 2013 it became the world's first biosimilar monoclonal antibody approved by the EMA.
Herzuma is a biosimilar trastuzumab approved by the MFDS for treatment of early and advanced HER2+ breast cancer as well as advanced stomach cancer. Herzuma is a HER2+ breast cancer therapy designed to treat aggressive HER positive metastatic and adjuvant breast cancer, as well as HER2 positive adenocarcinoma of the stomach that has spread.
Truxima is the first biosimilar of the reference monoclonal antibody rituximab that targets CD20 molecule primarily found on the surface of B-cells. Its target indications are rheumatoid arthritis, non-Hodgkin lymphoma and chronic lymphocytic leukemia.Annual Meeting 2013"> It was approved by the EMA in February 2017.